Skip to main content

Table 4 Sensitivity analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

No. Study that leave OR rate CR rate RR
Relative rate (95% CI) I2 (%) p-value Relative rate (95% CI) I2 (%) p-value Relative rate (95% CI) I2 (%) p-value
A4 Berentsen (2006) 1.09 (1.00, 1.19) 34.44 0.14 1.15 (0.98, 1.35) 48.37 0.05    
A12 Michel (2009) 1.20 (1.02, 1.40) 75.15 0.00 1.19 (0.99, 1.43) 56.56 0.02 0.96 (0.55, 1.71) 48.42 0.07
A18 Birgens (2013) 1.20 (1.03, 1.39) 74.94 0.00 1.18 (0.99, 1.41) 55.56 0.02    
A20 Barcellini (2014) 1.22 (1.02, 1.45) 75.07 0.00 1.21 (0.98, 1.48) 56.95 0.02 0.99 (0.54, 1.83) 46.25 0.08
A21 Roumier (2014) 1.18 (1.01, 1.37) 74.80 0.00 1.12 (0.95, 1.33) 47.14 0.06 0.90 (0.47, 1.73) 48.42 0.07
A23 Fu (2016) 1.22 (1.02, 1.46) 75.17 0.00 1.16 (0.97, 1.40) 56.23 0.02 0.88 (0.49, 1.56) 46.94 0.08
A27 Michel (2017) 1.15 (1.00, 1.32) 71.68 0.00 1.13 (0.96, 1.34) 48.94 0.05 0.96 (0.56, 1.65) 47.72 0.07
M7 Froissart (2012) 1.16 (0.99, 1.37) 71.24 0.00 1.15 (0.93, 1.41) 40.60 0.10 0.83 (0.49, 1.56) 39.83 0.13
M9 Hie (2014) 1.19 (1.02, 1.38) 75.20 0.00 1.18 (0.98, 1.44) 57.31 0.02 1.09 (0.74, 1.60) 0.00 0.47
M10 Khandelwal (2014) 1.23 (1.04, 1.46) 70.04 0.00 1.24 (1.03, 1.49) 25.52 0.22 0.83 (0.50, 1.35) 32.18 0.18